JiangSu WuZhong Pharmaceutical Development (SHA:600200) secured registration approval for eperisone hydrochloride active pharmaceutical ingredient (API) from China's drug regulator.
Eperisone hydrochloride is used for pain caused by muscle tension, according to a Wednesday filing with the Shanghai bourse.
Shares of the company rose less than 1% in recent trade.